ESC/EAS Guidelines for the management of dyslipidaemias
Рекомендации ESC/EAS по лечению дислипидемий: Рабочая группа Европейского общества кардиологов (ESC) и Европейского общества атеросклероза (EAS) по лечению дислипидемий
2011-01-01
SCID: 54.1/mdtaes95
Discuss with AI
ESC/EAS guidelinesatherosclerosiscardiovascular disease preventioncoronary artery diseasedyslipidaemia management
Figures from the paper
Abstract (AI)
Cardiovascular disease (CVD) due to atherosclerosis of the arterial vessel wall and to thrombosis is the foremost cause of premature mortality and of disability-adjusted life years (DALYs) in Europe, and is also increasingly common in developing countries.1 In the European Union, the economic cost of CVD represents annually E192 billion1 in direct and indirect healthcare costs. The main clinical entities are coronary artery disease (CAD), ischaemic stroke, and peripheral arterial disease (PAD). The causes of these CVDs are multifactorial. Some of these factors relate to lifestyles, such as tobacco smoking, lack of physical activity, and dietary habits, and are thus modifiable. Other risk factors are also modifiable, such as elevated blood pressure, type 2 diabetes, and dyslipidaemias, or non-modifiable, such as age and male gender. These guidelines deal with the management of dyslipidaemias as an essential and integral part of CVD prevention. Prevention and treatment of dyslipidaemias should always be considered within the broader framework of CVD prevention, which is addressed in guidelines of the Joint European Societies’ Task forces on CVD prevention in clinical practice.2 – 5 The latest version of these guidelines was published in 20075; an update will become available in 2012. These Joint ESC/European Atherosclerosis Society (EAS) guidelines on the management of dyslipidaemias are complementary to the guidelines on CVD prevention in clinical practice and address not only physicians [e.g. general practitioners (GPs) and cardiologists] interested in CVD prevention, but also specialists from lipid clinics or metabolic units who are dealing with dyslipidaemias that are more difficult to classify and treat.
Key Findings
1
Atherosclerotic cardiovascular disease and thrombosis are Europe’s leading causes of premature mortality and disability-adjusted life years, with substantial economic costs.
2
Dyslipidaemia prevention and treatment should be integrated with broader Joint European Societies’ cardiovascular prevention guidelines rather than considered in isolation.
3
Dyslipidaemias, alongside smoking, inactivity, diet, hypertension, and type 2 diabetes, are important modifiable cardiovascular risk factors.
4
The guidelines establish dyslipidaemia management as an essential, integral component of comprehensive cardiovascular disease prevention.
5
The recommendations address both general clinicians involved in prevention and lipid specialists managing difficult-to-classify or difficult-to-treat dyslipidaemias.
Research Object
Dyslipidaemias (disorders of blood lipids) as managed in clinical practice
Research Subject
The prevention and treatment management of dyslipidaemias, including their classification and management in difficult-to-treat cases
Publication Details
Publication Date
2011-01-01
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai3
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation2008
Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction2002
Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)1993
Cited by2
2016 European Guidelines on cardiovascular disease prevention in clinical practice2016
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC2012